Around 90% of LBCs are oestrogen receptor-positive and frequently respond well initially to adjuvant endocrine therapy with SERMS or aromatase inhibitors, however, a subset of LBC patients do not benefit from adjuvant endocrine therapy [21]. The gene discussed is CYP19A1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.